3-arylamino pyridine derivatives

Details 3-arylamino pyridine derivatives 3-arylamino pyridine derivatives

2011-06-07

2011-06-07

Chandrakumar, Nizal S (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S314000, C546S315000

Reexamination Certificate

active

07956191

ABSTRACT:
The invention provides novel, substituted 3-arylamino pyridine compounds (I) pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

REFERENCES:
patent: 4959378 (1990-09-01), Allen et al.
patent: 5525625 (1996-06-01), Bridges et al.
patent: WO 98/43960 (1998-10-01), None
patent: WO 99/01421 (1999-01-01), None
patent: WO 99/01426 (1999-01-01), None
patent: WO 00/41505 (2000-07-01), None
patent: WO 00/41994 (2000-07-01), None
patent: WO 00/42002 (2000-07-01), None
patent: WO 00/42003 (2000-07-01), None
patent: WO 00/42022 (2000-07-01), None
patent: WO 00/42029 (2000-07-01), None
patent: WO 00/68201 (2000-11-01), None
patent: WO 01/05391 (2001-01-01), None
patent: WO 01/68619 (2001-09-01), None
patent: WO 02/06213 (2002-01-01), None
patent: WO 03/035626 (2003-05-01), None
patent: WO 03/077855 (2003-09-01), None
patent: WO 03/077914 (2003-09-01), None
patent: WO 03/101988 (2003-12-01), None
patent: WO 2004/005284 (2004-01-01), None
patent: WO 2004/056789 (2004-07-01), None
patent: WO 2004091480 (2004-10-01), None
Orlova et al. STN Document No. 102:149069, Abstract of Izvestiya Sibirskogo Otdeleniya Akademii Nauk SSSR, Seriya Khimicheskikh Nauk (1984), (6), 93-7.
Bachman et al. Journal of Organic Chemistry (1949), 14, 97-104.
Talik, STN Accession No. 1953:435518 Abstract of Roczniki Chemii (1962), 36, 1465-75.
International Search Report, PCT/EP2005/011257, mailed Feb. 24, 2006.
International Preliminary Report on Patentability, PCT/EP2005/011257, issued Apr. 24, 2007.
Written Opinion of the International Searching Authority, PCT/EP2005/011257.
Carter, A., et al., “A Constitutive Active Mek → ERK Pathway Negatively Regulates NF-κB-dependent Gene Expression by Modulating TATA-binding Protein Phosphorylation,”The Journal of Biological Chemistry, 275(36): 27858-27864 (2000).
Chang, F., et al., “Signal Transduction Mediated by the Ras/Raf/MEK/ERK Pathway From Cytokine Receptors to Transcription Factors: Potential Targeting for Therapeutic Intervention,”Leukemia, 17: 1263-1293 (2003).
Crews, C., et al., “The Primary Structure of MEK, a Protein Kinase That Phosphorylates the ERK Gene Product,”Science, 258: 478-480 (1992).
Davies, H., et al., “Mutations of the BRAF Gene in Human Cancer,”Nature, 417: 949-954 (2002).
Dudley, D., et al., “A Synthetic Inhibitor of the Mitogen-activated Protein Kinase Cascade,”Proc. National Academy of Science U.S.A., 92: 7686-7689 (1995).
Huang, W., et al., “Biochemical and Biological Analysis of Mek1 Phosphorylation Site Mutants,”Molecular Biology of the Cell, 6: 237-245 (1995).
Kohl, N., et al., “Selective Inhibition of ras-Dependent Transformation by a Farnesyltransferase Inhibitor,”Science, 260: 1934-1937 (1993).
Lee, J., et al., “A Protein Kinase Involved in the Regulation of Inflammatory Cytokine Biosynthesis,”Nature, 372: 739-746 (1994).
Lee, P., et al., “ARRY-142886, A Potent and Selective MEK Inhibitor: III) Efficacy in Murine Xenograft Models Correlates With Decreased ERK Phosphorylation,”Proceedings of the American Association of Cancer Research, 45: Abs 3890 (2004).
Lewis, T., et al., “Signal Transduction Through MAP Kinase Cascades.” InAdvances in Cancer Research, George F. Vande Woude, et al., eds. (London: Academic Press), pp. 49-139 (1998).
Lin, A., et al., “Premature Senescence Involving p53 And p16 is Activated in Response to Constitutive MEK/MAPK Mitogenic Signaling,”Genes&Development, 12: 3008-3019 (1998).
McCubrey, J., et al., “Differential Effects of Viral and Cellular Oncogenes on the Growth Factor-Dependency of Hematopoietic Cells,”International Journal of Oncology, 7(2): 295-310 (1995).
McInnes, C., “Protein Kinases: Addressing the Challenges Across the Kinome—IIR's Second Annual Conference (Part I), Kinase Drug Discovery and Disease Biology, Amsterdam, the Netherlands,” (Reference No. RF511413). Amsterdam, the Netherlands: IDDB—Meeting Report (2003).
McInnes, C., “Protein Kinases: Addressing the Challenges Across the Kinome—IIR's Second Annual Conference (Part II), Clinical Update, New Therapies and New Technologies, Amsterdam, The Netherlands,” (Reference No. RF511633) Amsterdam, the Netherlands: IDDB—Meeting Report (2003).
Orlova, N., et al., “Interaction of Polyfluorosubstituted Pyridine and Naphthalene Carbonic Acids With Bromomagnezylaniline,”Sibirskogo Otdeleniya Akademii Nauk SSR Seriya Khimicheskikh Nauk, 17: 93-97 (1984).
Sherlock, M., et al., “Antiallergy Agents. 1. Substituted 1,8-Naphthyridin-2(1H)-ones as Inhibitors of SRS-A Release,”Journal of Medicinal Chemistry, 31: 2108-2121 (1988).
Steelman, L., et al., “JAK/STAT, Raf/MEK/ERK, Pl3K/Akt and BCR-ABL in Cell Cycle Progression and Leukemogenesis,”Leukemia, 18: 189-218 (2004).
Stirewalt, D., et al., “FLT3, RAS, And TP53 Mutations in Elderly Patients With Acute Myeloid Leukemia,”Blood, 97(11): 3589-3595 (2001).
Swanton, C., et al., “New Targets and Innovative Strategies in Cancer Treatment: One Year of Progress, Nice, France,” (Reference No. RF524997) France: IDDB—Meeting Report (2003).
Wallace, E., et al., “Preclinical Development of ARRY-142886, A Potent and Selective MEK Inhibitor,”Proceedings of the American Association of Cancer Research, 45: Abs 3891 (2004).
Waterhouse, D., et al., “A Phase 2 Study of an Oral MEK Inhibitor, CI-1040, in Patients With Advanced Nonsmall-cell Lung, Breast, Colon, or Pancreatic Cancer,”Proceedings of the American Society for Clinical Oncology, 22: Abs 816 (2003).
Yeh, T., et al., “ARRY-142886, A Potent and Selective MEK Inhibitor: II) Potency Against Cellular MEK Leads to Inhibition of Cellular Proliferation and Induction of Apoptosis in Cell Lines With Mutant Ras or B-Raf,”Proceedings of the American Association of Cancer Research, 45: Abs 3889 (2004).
Zhu, P., et al., “Studies of Antimalarials: Synthesis of Derivatives of Benzo[b][1,7] Naphthyridine With Aminophenol Mannich Base,”Gongye, 19(2): 55-57 (1988).

Affiliated with

Also associated with

Rating

3-arylamino pyridine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 3-arylamino pyridine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-arylamino pyridine derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2664175